Comparative Pharmacology
Head-to-head clinical analysis: LESSINA 21 versus LYBREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LESSINA 21 versus LYBREL.
LESSINA-21 vs LYBREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation. Causes cervical mucus thickening and endometrial alterations, impeding sperm penetration and implantation.
Combination of levonorgestrel and ethinyl estradiol: suppression of gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; thickening of cervical mucus to impede sperm penetration; alteration of endometrium to reduce implantation likelihood.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days placebo or no tablets.
One tablet (levonorgestrel 0.1 mg/ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets for 28-day cycle.
None Documented
None Documented
17-21 hours (terminal elimination half-life; clinical significance: allows once-daily dosing, but missed doses increase risk of ovulation)
Terminal elimination half-life: 27 ± 8 hours; requires ~5 days to reach steady-state; clinical significance: missed doses lead to rapid loss of contraceptive efficacy.
Renal (70% as unchanged drug and metabolites), fecal (30% as metabolites)
Renal: 50-60% as metabolites, ~20% as parent drug; fecal: 30-40%; biliary: 10-20%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive